Cipla Q3 Results, Jan. 23 -- Pharma major Cipla posted a massive 57% year-on-year (y-o-y) decline in its consolidated net profit for the third quarter of the ongoing fiscal on Friday, missing estimates.

The company posted a net profit of Rs.675.80 crore for Q3 FY26, as against Rs.1,570.51 crore in the same period last year.

Revenue from operations stood at Rs.7,074.48 crore, flat compared with Rs.7,072.97 crore in the corresponding period a year ago. A Bloomberg poll of 22 brokerages had pegged its revenue at Rs.7,530 crore and profit after tax at Rs.1,250 crore.

A production halt at its partner's manufacturing facility for its key US drug, Lanreotide, and a drop in sales of the blood cancer drug Revlimid, along with a one-time expense...